Resistance to Prostaglandin E2 Promotes Monocyte Activation During Chronic HIV Infection

Background. Monocyte activation is a driver of inflammation in the course of chronic HIV infection. Prostaglandin E2 (PGE2) is known to mediate anti-inflammatory effects, notably the inhibition of tumor necrosis factor-alpha (TNF-alpha) production by monocytes. We aim to investigate the effects of PGE2 on activation of monocytes in chronic HIV infection and the mechanisms through which PGE2 modulates their inflammatory signature.Methods. We recruited a group of people with HIV (PWH) and matched healthy uninfected persons. We compared plasma levels of PGE2, monocyte activation, and sensitivity of monocytes to the inhibitory actions mediated by PGE2.Results. We found increased plasma levels of PGE2 in PWH, and an activated phenotype in circulating monocytes, compared with uninfected individuals. Monocytes from PWH showed a significant resistance to the inhibitory actions mediated by PGE2; the concentration of PGE2 able to inhibit 50% of the production of TNF-alpha by lipopolysaccharide-stimulated monocytes was 10 times higher in PWH compared with uninfected controls. Furthermore, the expression of phosphodiesterase 4B, a negative regulator of PGE2 activity, was significantly increased in monocytes from PWH.Conclusions. Resistance to the inhibitory actions mediated by PGE2 could account, at least in part, for the inflammatory profile of circulating monocytes in PWH.

Automated summary

This study investigated the effects of prostaglandin E2 (PGE2) on monocyte activation in chronic HIV infection and the mechanisms through which PGE2 modulates their inflammatory signature. The results showed increased plasma levels of PGE2 and an activated phenotype in monocytes from people with HIV (PWH). Monocytes from PWH also exhibited resistance to the inhibitory actions mediated by PGE2, possibly contributing to their inflammatory profile.